commercial – Talk Bio

Rocket Pharmaceuticals Expands Leadership with J&J and AstraZeneca Alumni to Strengthen Gene Therapy Commercialization

2 weeks ago talkbio0Tagged AstraZeneca, Biotechnology, Chaudhuri, commercial, gene therapy, Kresladi, launch, Market, Mozafancogene Autotemcel, Rocket, Sarbani

Rocket Pharmaceuticals, gene therapy, commercial leadership, Sarbani Chaudhuri, Johnson & Johnson, AstraZeneca, commercial launch, gene therapy market, rare diseases, biotechnology, Kresladi, RP-L102.

BridgeBio Pharma Reports Strong Commercial Progress and Pipeline Updates for 2025

3 months ago talkbio0Tagged 2025, Attruby, BridgeBio Pharma, Clinical Trials, commercial, FORTIFY, Hereditary Diseases, milestones, Phase 3, Propel, status - In progress

BridgeBio Pharma, Attruby, commercial progress, pipeline updates, 2025 milestones, rare genetic diseases, Phase 3 clinical trials, FORTIFY, CALIBRATE, PROPEL 3.

Citius Oncology Explores Strategic Alternatives Ahead of LYMPHIR Commercial Launch

4 months ago talkbio0Tagged Citius Oncology, commercial, Immunotherapy, launch, LYMPHIR, strategic alternatives

Citius Oncology, LYMPHIR, strategic alternatives, commercial launch, cutaneous T-cell lymphoma, immunotherapy

Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns

4 months ago talkbio0Tagged commercial, gene therapy, Hemophilia A, partnership termination, Pfizer, Viable

Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination

Pleno Secures $25M Funding for Commercial Launch, Appoints New CEO from Illumina

4 months ago talkbio0Tagged CEO, commercial, Illumina, launch, Multiomics, Pleno

Pleno, multiomics, funding, commercial launch, new CEO, Illumina

Lexicon Pharmaceuticals Shifts Focus to Clinical Development Following FDA Setbacks

5 months ago talkbio0Tagged (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol, Chronic Kidney Diseases, Clinical Development, commercial, lexicon, restructuring, setbacks, Surgical aspects, United States Food and Drug Administration

Lexicon Pharmaceuticals, FDA setbacks, Clinical development focus, Commercial operations elimination, Sotagliflozin, Type 1 diabetes, Chronic kidney disease, Restructuring

Vertex’s CASGEVY Marks Historic Milestone with First Commercial Patient Infusions, Paving the Way for 2025 Launches

6 months ago talkbio0Tagged Anemia, Sickle Cell, Approved, Casgevy, commercial, CRISPR/Cas9, gene therapy, Infusion procedures, launches, United States Food and Drug Administration

CASGEVY, Vertex Pharmaceuticals, gene therapy, sickle cell disease, beta thalassemia, CRISPR/Cas9, FDA approval, commercial patient infusions, 2025 launches.